Patents by Inventor Yuriy Gankin

Yuriy Gankin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20220110941
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20220110940
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 14, 2022
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
    Patent number: 11202779
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: December 21, 2021
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20190298723
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 3, 2019
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20190290651
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
    Patent number: 10322128
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 18, 2019
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
    Patent number: 10314843
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 11, 2019
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20170296542
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20170296541
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey